Still, the overall number of molecular imaging papers is small compared with other categories, as this is only the second year the RSNA has had this section. Current topics of interest in molecular imaging include hyperpolarized carbon-13 imaging, smart MR agents, and use of PET/CT of all forms with new radiotracers.
Of the 6000 scientific abstracts submitted to the RSNA this year, four major areas dominate, according to Dr. Gerald Dodd III, chair of the RSNA's scientific program committee:
Still, the overall number of molecular imaging papers is small compared with other categories, as this is only the second year the RSNA has had this section. Current topics of interest in molecular imaging include hyperpolarized carbon-13 imaging, smart MR agents, and use of PET/CT of all forms with new radiotracers.
Cardiovascular studies jumped by 20%, mostly in CT, but with slight increases in cardiac MR as well, Dodd said. Research in cardiac CT includes better visualization of instent stenosis, the impact of extracardiac findings, and ER use of the triple rule out.
Given the positive results of the American College of Radiology Imaging Network trial on breast MR in high-risk women, it's no surprise that this topic will be well explored in the scientific sessions, along with breast ultrasound as an adjunct to mammography, according to Dodd. Tomosynthesis also gets its share of research space, in the breast as well as the chest.
Ultrasound has seen a decline in submissions, especially by U.S. radiologists, over the years. It seems, though, that ultrasound research is integrated into the organ systems by subspecialists such as musculoskeletal and abdominal radiologists.
With the excitement of a major ACRIN trial behind it, CT colonography continues to be a hot topic. Researchers are particularly looking at ways to standardize reporting and use computer-aided detection effectively. There will be a workshop dedicated to exploring aspects of nephrogenic systemic fibrosis, as well as a number of scientific presentations on the topic.
As in the past, the number of international submissions has increased, while the North American submissions remained stable. The largest jump came from China.
FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
June 11th 2025Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.